BEIJING, Nov. 24 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that management is scheduled to present at the Piper Jaffray Health Care Conference on Wednesday, December 2, 2009 at 8 a.m. Eastern time. The conference is scheduled for December 1-2 at the New York Palace in New York, NY.

 

A live webcast of the presentation will be available online on the Investor Relations home page of Sinovac's corporate Web site at http://www.sinovac.com .

 

About Sinovac

 

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

 

    For more information, please contact:

    Helen G. Yang
    Sinovac Biotech Ltd.
    Tel:   +86-10-8289-0088 x9871
    Fax:   +86-10-6296-6910
    Email: info@sinovac.com

   Investors:
    Amy Glynn/Stephanie Carrington
    The Ruth Group
    Tel:   +1-646-536-7023/7017
    Email: aglynn@theruthgroup.com
           scarrington@theruthgroup.com

   Media:
    Janine McCargo
    The Ruth Group
    Tel:   +1-646-536-7033
    Email: jmccargo@theruthgroup.com

Original:sinovac